ERBB2 and non-small cell lung carcinoma: Overall, most of the samples (74.5%, 2261/3035) in the NSCLC-BM cohort featured one or more CDx-associated biomarker(s) (ALK, ROS1, NTRK1/2/3 fusions; EGFR Exon19del, L858R, T790M; BRAF V600E; MET exon 14 skipping mut; RET rearrangement; and KRAS G12C) or an NCCN recommended targetable biomarker (ERBB2 mutations; MET amplifications) (Fig. 2).